MDACC Study No:2011-0374 ( NCT No: NCT01430351)
Title:A Phase I Lead-in to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
Principal Investigator:Marta Penas-Prado
Treatment Agent:Mefloquine; Memantine; Metformin; Temozolomide
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of temozolomide in combination with memantine, mefloquine, and/or metformin
that can be given to patients with glioblastoma who have already been given
radiation and chemotherapy in combination. The safety of these drug
combinations will also be studied.

Temozolomide is designed to kill cancer cells by damaging DNA (the genetic
material of cells). The damaged DNA may cause tumor cell death.

Memantine is designed to block the activity of a protein found on the surface
of cells that may control tumor growth and survival. This may stop further
spread of tumor cells.

Mefloquine is designed to block a protein that helps to clean the waste in the
cells and to destabilize the cell membrane. Blocking this protein may cause
tumor cell death.

Metformin is designed to block a protein in tumor cells that is important in
tumor growth and blood vessel development. This may cause cell death or reduce
the spread of the disease.
Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I
Treatment Agents:Mefloquine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marta Penas-Prado
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults